Skip to main content

24-10-2018 | Breast cancer | Video

PALOMA-3 defines a new standard of care for advanced breast cancer

Massimo Cristofanilli discusses the latest results from the PALOMA-3 trial investigating the addition of the CDK4/6 inhibitor palbociclib to fulvestrant in previously treated advanced breast cancer (5:21).

Funding for this video was provided in part by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits